Additionally, EGFR-mutant NSCLC tumors had markedly less crosstalk between T cells and other cell types via the PD-1/PD-L1 pathway than EGFR-negative NSCLCs [116]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.